Tag: Business and Industry

Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy

March 15, 2019 todi0

At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form […]

Merck announces collaboration with Iktos for generative artificial intelligence (AI) technology

March 14, 2019 todi0

Merck, a leading science and technology company, today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds. “This agreement is another illustration of how we aim to enrich our discovery engine with […]

Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW

March 11, 2019 todi0

Sandoz, a Novartis division, announced the winners of the 2019 Sandoz Healthcare Access Challenge (HACk). Sandoz HACk invites entrepreneurs and innovators in the field of digital technology to submit ideas with the potential to complement – or even positively disrupt – established approaches to driving access to healthcare. The three winners, chosen from over 400 […]

Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition

March 7, 2019 todi0

The Bayer Cares Foundation recently presented the 2018 Aspirin Social Innovation Awards to five international initiatives for their groundbreaking ideas in the fields of healthcare and nutrition. The award-winners are all impact pioneers whose concepts have the potential to bring about sustainable, systematic changes to thus improve the living conditions of hundreds of millions of […]

Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors

March 5, 2019 todi0

Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic® (semaglutide) 1.0 mg when added to SGLT-2 inhibitor (SGLT-2i) therapy. (1) In SUSTAIN 9, adults with type 2 diabetes were […]

Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China

March 4, 2019 todi0

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and […]

Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin

February 28, 2019 todi0

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 prize to Dr. Changjun Yin from the Institute for Cardiovascular Prevention at the Ludwig-Maximilians-University in Munich in recognition of his research on Atherosclerosis and Alzheimer’s disease (AD) as inflammatory […]

Jury upholds Amgen’s patents on Repatha® (evolocumab)

February 27, 2019 todi0

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen’s favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amgen’s innovative Repatha® (evolocumab) product, that bind to a specific region on PCSK9 and reduce LDL-C levels in the body. This verdict follows a […]

Roche enters into definitive merger agreement to acquire Spark Therapeutics

February 26, 2019 todi0

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction. This corresponds to a total transaction value of approximately US$ 4.3 billion on a fully diluted basis.

Brilinta’s Phase III THEMIS trial met primary endpoint in  patients with established coronary artery disease and type-2 diabetes

February 25, 2019 todi0

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone. THEMIS was conducted in over 19,000 patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior […]